Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
RESEARCH TOOLSreports
ARCT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.30 - $45.00
Previous CloseN/A
Volume109.32K
Average Volume (3M)426.81K
Market Cap
$488.93M
Enterprise Value$365.35M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.84
Next Earnings
Mar 03, 2025EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding27,087,358
10 Day Avg. Volume447,471
30 Day Avg. Volume426,812
Standard Deviation0.32
R-Squared0.18
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.05
Price to Cash Flow (P/CF)-5.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.36
Enterprise Value/Ebitda-6.16
Forecast
1Y Price Target
$76.60Price Target Upside342.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Financial MilestonesArcturus is eligible for up to $4.3B in development and commercial milestones in its agreement with CSL, one of the largest influenza vaccine providers in the world.
Manufacturing And DistributionApproval to manufacture Kostaive in Japan at the ARCALIS facility is an important point of progress for Kostaive in Japan.
Vaccine ApprovalKostaive is the first sa-mRNA COVID-19 vaccine approved by the European Commission, which applies to all EU member states and European Economic Area countries.
Bears Say
Cost OffsetsThe initial revenue from the Japan COVID-19 vaccine order will be offset by 40% of past development costs, requiring significant sales to cover these expenses.
Revenue RecognitionARCT revenue recognition is still to be determined and likely delayed as Meiji reports revenue to CSL, who then calculates and reports to ARCT its share after cost offsets.
Safety And Efficacy RisksKey risks to the rating and price target include unforeseen safety or tolerability issues with ARCT-154, ARCT-810, or ARCT-032, and failure of Arcturus' mRNA drugs to be effective in human clinical trials.
---
Ownership Overview
8.44% Insiders
30.79% Mutual Funds
0.30% Other Institutional Investors
39.02% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $14.30 and its highest was $45.00 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Arcturus Therapeutics’s market cap is $488.93M.
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is Mar 03, 2025 which is in 11 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$1.216 by $0.956.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics does not currently pay dividends.
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -0.55.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 27,087,358 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$0.26 in its last earnings report, beating expectations of -$1.216. Following the earnings report the stock price went up 4.696%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Currently, no hedge funds are holding shares in ARCT
---
Arcturus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$76.60 (342.26% Upside)
$76.60 (342.26% Upside)
Blogger Sentiment
Bullish
ARCT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 167.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.03%
12-Months-Change
Fundamentals
Return on Equity
-21.96%
Trailing 12-Months
Asset Growth
-19.01%
Trailing 12-Months
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
---
ARCT Company Deck
---
ARCT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted the successful commercial launch of KOSTAIVE in Japan and positive clinical trial results, indicating significant progress in Arcturus' pipeline. However, financial challenges such as a decrease in revenue and a reported net loss, along with delays in data for the OTC program, were noted. Overall, the sentiment is balanced with notable achievements and ongoing challenges.Read More>---
ARCT Stock 12 Month Forecast
Average Price Target
$76.60
▲(342.26% Upside)
Technical Analysis
Best Analysts Covering ARCT
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-22.07%
reiterated a buy rating 3 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -22.07% per trade.
---